The universal cell-cycle inhibitor p21 Cip1/WAF1 is phosphorylated ... as a mechanism of deregulating cell proliferation in cancer. Figure 1: Oncogene Her2/neu-initiated, Akt-mediated p21 Cip1 ...

I believe Cyclin-Dependent Kinase 9 (CDK9) inhibitors are one modality that will bring us a step closer to that future. By targeting the fundamental processes that enable cancer cell survival ...

How IDO exerts its immunomodulatory effects is not completely clear and two main theories have been proposed involving tryptophan metabolites or starving cells ... using IDO for cancer therapy ...

In addition, studies have shown that in tumour cells which are deficient in the tumour suppressor p53, CHK1 inhibition will sensitise these cells to genotoxic cancer treatments. Inhibitors of this ...

In the past, this labs study of G1 cyclins and the Kip family of cdk inhibitors contributed greatly to our understanding of the consequences, both cellular and organismal, of dysregulating the ...

Fadraciclib is under clinical development by Cyclacel Pharmaceuticals and currently in Phase II for Uterine Cancer.

Esophageal squamous cell carcinoma (ESCC) is a severe health threat, being a predominant subtype of esophageal cancer and ...

My laboratory has combined biochemical, molecular, cellular, and genetic approaches to investigate the roles of CDK inhibitors in differentiation ... the genes and and molecular mechanisms by which ...

Findings demonstrate that the tested combination achieved durable and significant responses in patients with non-squamous non-small cell lung cancer (NSCLC) and urothelial cancer, two tumor types ...

The event, which runs from December 10-13, brings together global leaders in breast cancer research ... targets tumor cells with oncogenic alterations that cause cell cycle dysregulation.

Award follows extensive pre-clinical, single agent activity data generated by Prof. Colleen Nelson's lab at QUT in 'Aggressive Variant' prostate ca ...